<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nontuberculous mycobacterial lymphadenitis in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nontuberculous mycobacterial lymphadenitis in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nontuberculous mycobacterial lymphadenitis in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrea T Cruz, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2272512883">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [
         <a href="#rid1">
          1
         </a>
         ]. They have been isolated from numerous environmental sources, including water, soil, food products, and domestic and wild animals [
         <a href="#rid2">
          2
         </a>
         ]. Health care-associated transmission has occurred with medical equipment [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
         This topic will provide an overview of NTM lymphadenitis in children. NTM skin and soft tissue infections, pulmonary infections, disseminated infections, and bacteremia in children are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85895.html" rel="external">
          "Nontuberculous mycobacterial skin and soft tissue infections in children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85894.html" rel="external">
          "Nontuberculous mycobacterial pulmonary infections in children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14425.html" rel="external">
          "Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272512896">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         More than 170 species of nontuberculous mycobacterial (NTM) have been identified, not all of which have been documented to cause disease in humans [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – NTM pathogens are classified as rapidly growing or slowly growing (
         <a class="graphic graphic_table graphicRef61936" href="/z/d/graphic/61936.html" rel="external">
          table 1
         </a>
         ). Rapidly growing species grow within seven days and include
         <em>
          Mycobacterium fortuitum, Mycobacterium abscessus,
         </em>
         <em>
          Mycobacterium chelonae, Mycobacterium smegmatis,
         </em>
         and
         <em>
          Mycobacterium mucogenicum
         </em>
         . Slowly growing species require several weeks to grow and include
         <em>
          Mycobacterium avium
         </em>
         complex (MAC),
         <em>
          Mycobacterium marinum,
         </em>
         and
         <em>
          Mycobacterium kansasii
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria", section on 'Classification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease associations
         </strong>
         – NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenitis, skin and soft tissue infection, pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In case series of nontuberculous mycobacterial lymphadenitis among children in the United States, the majority of cases occur in previously healthy children and are caused by MAC, which includes
         <em>
          M. avium
         </em>
         and
         <em>
          Mycobacterium intracellulare
         </em>
         [
         <a href="#rid2">
          2,10,11
         </a>
         ]. In series from other countries, MAC and
         <em>
          Mycobacterium haemophilum
         </em>
         are frequently isolated [
         <a href="#rid12">
          12-18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272512904">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable; in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [
         <a href="#rid2">
          2
         </a>
         ]. Nonetheless, the overall prevalence of NTM disease appears to be increasing (possibly as a result of enhanced detection) [
         <a href="#rid10">
          10,19-22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         In population-based surveillance studies, estimates of the annual incidence of NTM in children range widely: from 0.6 to 1.6 per 100,000 children in Australia, to 3.1 per 100,000 children in Germany, to 77 per 100,000 children in the Netherlands [
         <a href="#rid23">
          23-26
         </a>
         ]. In each of these studies, lymphadenitis was the most common presentation. In a multicenter case series from Germany and Austria, children with NTM lymphadenitis were more likely to seek treatment during the colder months [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         NTM are transmitted through environmental sources.
         <em>
          M. avium
         </em>
         complex (MAC), the most common cause of lymphadenitis, is found in soil and water (from both natural and treated water) [
         <a href="#rid28">
          28-32
         </a>
         ]. Aquatic transmission of NTM is facilitated by the formation of biofilms, which permit survival under a variety of environmental conditions and allow dissemination of large numbers of organisms when they become detached [
         <a href="#rid33">
          33
         </a>
         ]. In surveillance from Australia, where reporting of NTM species is mandatory,
         <em>
          M. haemophilum
         </em>
         infections in children increased following episodes of severe flooding [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Children with a history of bacille Calmette-Guérin (BCG) immunization appear to have a reduced risk of MAC lymphadenitis [
         <a href="#rid34">
          34
         </a>
         ]. Conversely, the risk NTM infection, including NTM lymphadenitis, appears to increase following countrywide discontinuation of mandatory BCG immunization [
         <a href="#rid17">
          17,35-37
         </a>
         ].
        </p>
        <p>
         The oropharyngeal mucosa is the typical portal of entry for NTM cervical lymphadenitis. Lymphadenitis in other sites may follow penetrating trauma [
         <a href="#rid10">
          10,38
         </a>
         ].
        </p>
        <p>
         The incubation periods are variable [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2272512912">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in childhood. It typically occurs in children between one and five years of age [
         <a href="#rid10">
          10,13,26,39
         </a>
         ]. The cervicofacial nodes, particularly the submandibular nodes, are most frequently involved [
         <a href="#rid10">
          10,18,26,40
         </a>
         ]. Lymph nodes outside the head and neck, including hilar or mediastinal nodes, may also be involved. Some children have associated odontogenic infections and/or a history of recent dental care or procedures [
         <a href="#rid41">
          41
         </a>
         ]. Outbreaks of NTM infections have been reported among children who underwent dental procedures in clinics where the dental treatment water contained high levels of bacteria [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
         NTM lymphadenitis generally presents as a unilateral, nontender node (&lt;4 cm in diameter) that slowly enlarges over several weeks [
         <a href="#rid44">
          44
         </a>
         ]. Lymph nodes enlarge in the path of least resistance, often becoming tethered to the overlying skin. The overlying skin then gradually changes from pink to violaceous and thins to become parchment-like (
         <a class="graphic graphic_picture graphicRef69475" href="/z/d/graphic/69475.html" rel="external">
          picture 1
         </a>
         ) and may eventually suppurate through a sinus tract [
         <a href="#rid1">
          1,10,26,44
         </a>
         ]. Sinus tract formation can occur spontaneously or follow direct trauma to the region. Fever and other systemic findings are variable and are more common if the lymph nodes become secondarily infected by pyogenic bacteria (eg, staphylococcal or streptococcal species) [
         <a href="#rid24">
          24,25
         </a>
         ]. If prescribed, antibiotics directed against staphylococci or streptococci generally are not helpful [
         <a href="#rid1">
          1,22,44,45
         </a>
         ]. These features do not reliably differentiate NTM from
         <em>
          Mycobacterium tuberculosis
         </em>
         lymphadenitis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Delay in diagnosis is common. In a series of 105 patients, the time between onset of swelling and diagnosis was typically four to eight weeks (median 6.5 weeks, range eight days to two years) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The clinical features of NTM lymphadenitis have been described in several case series, each including &gt;100 children [
         <a href="#rid10">
          10,24,26,39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The submandibular nodes were involved in 87 percent, followed by preauricular (9 percent) and submental (3 percent) nodes; supraclavicular node involvement was uncommon [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nearly all cases of cervical adenitis were unilateral (89 to 99 percent) [
         <a href="#rid10">
          10,24,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Violaceous discoloration and fluctuance were present in 85 percent [
         <a href="#rid39">
          39
         </a>
         ] but often are not present at the time lymphadenopathy is first noted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever (temperature &gt;38.5°C [101.3°F]) was present in 13 to 21 percent [
         <a href="#rid24">
          24,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one series, a fistula developed in 14 of 84 patients (16.7 percent) [
         <a href="#rid24">
          24
         </a>
         ]; in another, a draining sinus tract was noted on follow-up ultrasonography in 62 of 66 (93 percent) patients who were initially treated with antibiotics but without excision [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Development of a fistula often is preceded by fluctuance in the node, thinning of the overlying skin, and tethering of the node to the skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymph nodes in addition to those in the cervicofacial region were involved in 15 percent of cases in one series (86 percent of such cases were caused by
         <em>
          M. haemophilum
         </em>
         , 14 percent by
         <em>
          M. avium
         </em>
         ) and 29 percent in another [
         <a href="#rid10">
          10,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272512920">
         <span class="h1">
          RADIOGRAPHIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging studies are not necessary in the routine evaluation of a child with suspected nontuberculous mycobacterial (NTM) adenitis but may be helpful in evaluating other conditions in the differential diagnosis of cervical adenitis [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5982.html" rel="external">
          "Cervical lymphadenitis in children: Etiology and clinical manifestations"
         </a>
         .)
        </p>
        <p>
         Ultrasonographic features of NTM lymphadenitis were described in case series in which ultrasonography was performed on 145 children who participated in a clinical trial [
         <a href="#rid39">
          39
         </a>
         ]. Early in the disease course, decreased echogenicity was noted in all patients; in the advanced stages, 92 percent had intranodal liquefaction, matted nodes, and soft tissue edema. In a case series of 138 children with NTM lymphadenitis, intranodal liquefaction was strongly associated with unfavorable outcome (defined as symptoms lasting &gt;12 months, requiring &gt;1 surgical intervention, facial nerve palsy, major complications, or substantial scarring) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Computed tomography findings of NTM lymphadenitis include ring enhancement with central hypodensity and minimal to absent fat stranding; the lack of fat stranding may help to differentiate NTM from pyogenic lymphadenitis [
         <a href="#rid39">
          39,47,48
         </a>
         ].
        </p>
        <p>
         Chest radiograph (frontal and lateral) may be performed to look for signs of pulmonary tuberculosis or malignancy (eg, hilar adenopathy). The lateral radiograph is particularly important in young children in whom the thymic silhouette may obscure assessment of the mediastinum on the frontal view. The chest radiograph is typically normal in children with NTM lymphadenitis [
         <a href="#rid2">
          2,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2272512928">
         <span class="h1">
          LABORATORY FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with nontuberculous mycobacterial (NTM) lymphadenitis usually have normal complete blood count (CBC), differential, and erythrocyte sedimentation rate (ESR) [
         <a href="#rid19">
          19,26
         </a>
         ]. Abnormal findings in the CBC and/or elevated ESR should prompt consideration of other conditions in the differential diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/5982.html" rel="external">
          "Cervical lymphadenitis in children: Etiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         .)
        </p>
        <p>
         Histopathology and acid-fast bacilli stains are discussed below. (See
         <a class="local">
          'Microbiology and histopathology'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2272512951">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2272512967">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nontuberculous mycobacterial (NTM) lymphadenitis should be suspected in young children (&lt;5 years) with subacute/chronic (ie, weeks to months), unilateral, nontender, cervicofacial lymphadenitis that fails to improve or worsens despite antibiotic therapy directed against staphylococci and streptococci (if such therapy has been provided) [
         <a href="#rid1">
          1
         </a>
         ]. Patients are usually well appearing without constitutional symptoms.
        </p>
        <p>
         The clinical course and appearance of NTM adenitis, particularly when the overlying skin becomes violaceous and thin, often is so characteristic that a presumptive diagnosis can be made based upon the history and physical examination (
         <a class="graphic graphic_picture graphicRef69475" href="/z/d/graphic/69475.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         However, early in the course of disease, particularly before the skin becomes violaceous, other conditions in the differential diagnosis may appear more likely, and evaluation and treatment for such conditions may be undertaken before NTM is suspected. This evaluation may include complete blood count with differential and erythrocyte sedimentation rate, tuberculin skin testing (TST), interferon gamma release assay (IGRA), imaging, and/or serologic testing (as clinically indicated for
         <em>
          Bartonella henselae
         </em>
         , Epstein-Barr virus, cytomegalovirus, human immunodeficiency virus [HIV], toxoplasmosis, etc). (See
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management", section on 'Subacute/chronic'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H750699842">
         <span class="h2">
          Preliminary differentiation from
          <i>
           M. tuberculosis
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is particularly important to try to distinguish between NTM and
         <em>
          M. tuberculosis
         </em>
         lymphadenitis because they have different public health and treatment implications [
         <a href="#rid2">
          2
         </a>
         ]. Although detection of NTM with culture or polymerase chain reaction (PCR) assay is necessary for definitive diagnosis, the TST and IGRAs may be helpful in differentiating NTM from
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ]. TST and IGRA are typically performed on the same day (
         <a class="graphic graphic_algorithm graphicRef131706" href="/z/d/graphic/131706.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         The TST contains numerous antigens shared by
         <em>
          M. tuberculosis
         </em>
         and NTM species. IGRAs are in vitro blood tests of cell-mediated immune response; they measure T cell release of interferon-gamma following stimulation by antigens unique to
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid51">
          51
         </a>
         ]. They do not cross react with the NTM species that most frequently cause lymphadenitis (
         <em>
          M. avium
         </em>
         complex [MAC],
         <em>
          M. haemophilum, Mycobacterium scrofulaceum
         </em>
         )
         <em>
         </em>
         or with bacille Calmette-Guérin (BCG) immunization (which uses an attenuated form
         <em>
          of Mycobacterium bovis
         </em>
         ), but they may cross react with other NTM species, including
         <em>
          M. marinum, Mycobacterium szulgai, M. kansasii, Mycobacterium flavescens,
         </em>
         wild type
         <em>
          M. bovis, Mycobacterium gastri, and Mycobacterium riyadhense
         </em>
         [
         <a href="#rid52">
          52,53
         </a>
         ]. The TST and IGRAs are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children", section on 'How to test'
         </a>
         .)
        </p>
        <p>
         The interpretation of TST and IGRA in children with lymphadenitis depends upon the size of induration, risk factors for
         <em>
          M. tuberculosis
         </em>
         (eg, contact with a person with
         <em>
          M. tuberculosis
         </em>
         disease, residence in or travel to an area where
         <em>
          M. tuberculosis
         </em>
         is endemic), and receipt of BCG vaccination. In immunocompromised children, the sensitivity of TST and IGRA is decreased, and results should be interpreted with caution [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TST with ≥5 mm induration
         </strong>
         <em>
          –
         </em>
         TST with ≥5 mm of induration at 48 hours may be due to NTM (usually in children without risk factors for
         <em>
          M tuberculosis
         </em>
         ),
         <em>
          M. tuberculosis
         </em>
         (usually in children with risk factors for
         <em>
          M. tuberculosis
         </em>
         ), or false positive result from BCG immunization (if the child received BCG) [
         <a href="#rid2">
          2,12,46,50,55
         </a>
         ]. TST ≥15 mm may be more suggestive
         <em>
          of M. tuberculosis
         </em>
         than NTM but does not exclude NTM or reaction to BCG. IGRA results may help to differentiate between these possibilities (
         <a class="graphic graphic_algorithm graphicRef131706" href="/z/d/graphic/131706.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive IGRA suggests
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Negative IGRA suggests either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         NTM in children who have not received BCG.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In a study of 174 children with cervicofacial lymphadenitis who had no exposure
         <em>
          to M. tuberculosis
         </em>
         and had not received BCG vaccination, TST with &gt;5 mm of induration at 48 hours had a sensitivity of 70 percent, specificity of 98 percent, positive predictive value of 98 percent, and negative predictive value of 64 percent for NTM (confirmed by positive culture and/or PCR) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         False positive TST related to BCG immunization if the child received BCG; IGRAs do not interact with the attenuated form of
         <em>
          M. bovis
         </em>
         that is used in BCG immunization.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Indeterminate IGRA does not help differentiate NTM from
         <em>
          M. tuberculosis.
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TST with no induration or induration of &lt;5 mm
         </strong>
         – TST with no induration or induration of &lt;5 mm at 48 hours does not exclude mycobacterial disease. In these children (
         <a class="graphic graphic_algorithm graphicRef131706" href="/z/d/graphic/131706.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive IGRA suggests
         <em>
          M. tuberculosis.
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Negative or indeterminate IGRA may indicate either NTM (in a child with characteristic clinical features such as violaceous discoloration and thinning of the skin or a fistulous tract) or an alternate diagnosis. (See
         <a class="local">
          'Other conditions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1298253072">
         <span class="h2">
          Laboratory confirmation
         </span>
        </p>
        <p class="headingAnchor" id="H2435086332">
         <span class="h3">
          Obtaining and processing specimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specimens for microbiologic and histopathologic studies in children with suspected NTM may be obtained through excisional biopsy, fine needle aspiration (FNA), or fistulous drainage. If there is a strong suspicion of NTM, excisional biopsy often is undertaken because it is curative; in addition, the yield is usually better than with FNA because more tissue is available for culture. FNA can increase microbiologic yield when excisional biopsy may not be an option (eg, proximity of the affected node to the facial nerve) and is infrequently associated with fistulous complications [
         <a href="#rid1">
          1,2,47,57
         </a>
         ]. However, some advocate FNA for obtaining diagnostic material [
         <a href="#rid13">
          13,58
         </a>
         ]. FNA cytology can rapidly provide accurate information and has excellent concordance with biopsy samples sent for culture [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
         Incision and drainage generally are contraindicated if NTM is suspected because of the risk of recurrence or development of a chronically draining fistula [
         <a href="#rid1">
          1,59-62
         </a>
         ]. However, incision and drainage may have been performed before NTM was suspected. (See
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         .)
        </p>
        <p>
         It is helpful to discuss specimen collection, transport, and processing with the microbiology laboratory before sending tissue or fluid samples for suspected NTM. Swabs of tissue or fluid samples have lower culture yield and are not recommended [
         <a href="#rid63">
          63
         </a>
         ]; preferred samples include tissue samples or nodal fluid. Some species of NTM (eg,
         <em>
          M. haemophilum
         </em>
         ) have fastidious growth requirements.
        </p>
        <p class="headingAnchor" id="H1034223532">
         <span class="h3">
          Microbiology and histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of NTM in culture or PCR of fistula drainage, tissue, or caseous material confirms the diagnosis of NTM lymphadenitis [
         <a href="#rid1">
          1,2,10,19
         </a>
         ]. Tissue specimens and/or aspirated fluid or pus should be sent for mycobacterial culture, PCR, acid-fast bacilli (AFB) stains, and histopathology (in addition to bacterial and fungal stains and cultures, and cytopathology as clinically indicated).
        </p>
        <p>
         Pending culture results or if NTM is not detected, positive AFB stains and characteristic histopathology can help to establish a presumptive diagnosis in children with characteristic clinical features (eg, subacute/chronic unilateral lymphadenitis, violaceous discoloration) if other conditions in the differential diagnosis have been excluded [
         <a href="#rid1">
          1,10,19,47,58
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterial culture
         </strong>
         – A positive culture confirms the diagnosis of NTM lymphadenitis. However, isolation and identification of the NTM species may take longer than six weeks [
         <a href="#rid12">
          12
         </a>
         ]. The yield of positive NTM cultures from excised lymph nodes ranges from 50 to 80 percent [
         <a href="#rid2">
          2,10
         </a>
         ]. The yield is usually lower for specimens obtained through FNA, though yields of up to 80 percent have been reported [
         <a href="#rid13">
          13
         </a>
         ]. Microbiologic techniques to maximize the yield of NTM cultures are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria", section on 'Culture'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among children with a negative culture or in whom culture results are pending, a presumptive diagnosis of NTM lymphadenitis can be made if the clinical (eg, subacute/chronic nontender, unilateral lymphadenitis, violaceous discoloration) and/or histopathologic features (eg, positive stains for AFB, granulomas) are compatible with NTM and other conditions in the differential diagnosis (including
         <em>
          M. tuberculosis
         </em>
         ) have been excluded [
         <a href="#rid1">
          1,10,19,47,58
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Laboratory features'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PCR
         </strong>
         – The diagnosis of NTM infection can be established with species-specific or multiplex PCR testing [
         <a href="#rid2">
          2,64-66
         </a>
         ]. PCR tests that can identify MAC soon after growth is evident are commercially available [
         <a href="#rid67">
          67
         </a>
         ]. In a study of 67 children with mycobacterial adenitis and 50 children with cat scratch disease, the sensitivity and specificity of mycobacterial PCR were 72 and 100 percent, respectively [
         <a href="#rid64">
          64
         </a>
         ]. The performance of PCR is based upon the quality of the specimen. Sending lymphatic tissue for culture and molecular testing is superior to sending exudative material.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AFB stains and histopathology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Features
         </strong>
         – Histopathologic features of NTM lymphadenitis include caseating granulomas, necrotizing granulomas, granulomatous and pyogenic inflammation, mononuclear inflammation, fibrocaseous reactions, multinucleated giant cells, and microabscesses [
         <a href="#rid10">
          10,47,68
         </a>
         ]. These histologic features overlap with those of
         <em>
          M. tuberculosis
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria", section on 'Microscopy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Interpretation
         </strong>
         – Although positive stains for AFB and histopathology with characteristic features support a diagnosis of mycobacterial infection, positive AFB stains do not distinguish among NTM species or between NTM species and
         <em>
          M. tuberculosis
         </em>
         . In addition, positive AFB staining in children with NTM lymphadenitis is variable. Negative AFB stains do not exclude mycobacterial disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H369884209">
         <span class="h2">
          Subsequent evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a previously healthy child, detection of an NTM species in a lymph node is not an indication for routine immunologic evaluation. Most cases of NTM lymphadenitis occur in immunocompetent children.
        </p>
        <p>
         Immunologic evaluation may be warranted for children with NTM lymphadenitis who have recurrent, deep, or systemic NTM infections; systemic symptoms at the onset of lymphadenitis; NTM lymphadenitis outside the head and neck region; or a family history of consanguinity and/or infant deaths [
         <a href="#rid69">
          69
         </a>
         ]. Cervicofacial lymphadenitis has been associated with FCHO1 deficiency (a novel type of combined immunodeficiency impaired T-cell proliferation, among other defects) and Mendelian susceptibility to mycobacterial diseases. (See
         <a class="medical medical_review" href="/z/d/html/89801.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: An overview", section on 'Presentation and clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">
          "Combined immunodeficiencies: Specific defects", section on 'FCHO1 deficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2272513023">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of nontuberculous mycobacterial (NTM) lymphadenitis includes other infectious causes of unilateral lymphadenitis (eg,
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Streptococcus pyogenes
         </em>
         ,
         <em>
          B. henselae
         </em>
         ,
         <em>
          M. tuberculosis
         </em>
         , viral infections, toxoplasmosis), benign cysts, and malignancy [
         <a href="#rid1">
          1,10,49,70
         </a>
         ]. Historical, examination, and laboratory findings (eg, blood counts, erythrocyte sedimentation rate, serology) may be helpful in differentiating NTM lymphadenitis from these conditions. (See
         <a class="medical medical_review" href="/z/d/html/5982.html" rel="external">
          "Cervical lymphadenitis in children: Etiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2272513031">
         <span class="h2">
          <i>
           M. tuberculosis
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is particularly important to try to distinguish between NTM and
         <em>
          M. tuberculosis
         </em>
         lymphadenitis because they have different public health and treatment implications [
         <a href="#rid2">
          2
         </a>
         ]. Culture is necessary for definitive diagnosis. (See
         <a class="local">
          'Preliminary differentiation from M. tuberculosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8001.html" rel="external">
          "Tuberculous lymphadenitis", section on 'Cervical lymphadenopathy'
         </a>
         .)
        </p>
        <p>
         No clinical or histopathologic feature reliably differentiates NTM from
         <em>
          M. tuberculosis
         </em>
         lymphadenitis. However, in observational studies, certain features were more suggestive of NTM [
         <a href="#rid11">
          11,49,68
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Younger age (eg, preschool)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of risk factors for tuberculosis, including being born in a country with low prevalence of
         <em>
          M. tuberculosis
         </em>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal chest radiograph
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative tuberculin skin testing (TST) results in family members
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative interferon gamma release assay
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ill-defined (nonpalisading), irregular, serpiginous, or sarcoid granulomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymorphonuclear leukocytes in center of areas of necrosis rather than diffusely scattered
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of significant caseation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microabscesses
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272513039">
         <span class="h2">
          Other conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to lymphadenitis due to other bacterial pathogens, NTM lymphadenitis has a more subacute/chronic course, lacks warmth and tenderness, and often has overlying violaceous skin discoloration; TST testing may be positive, but other laboratory findings usually are normal. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5982.html" rel="external">
          "Cervical lymphadenitis in children: Etiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2272513047">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of nontuberculous mycobacterial (NTM) lymphadenitis in children may require surgery and/or antimycobacterial therapy, in combination or sequentially. When discussing the benefits and risks of these modalities, caregivers should be advised that clinical response to both surgical and medical management may be incomplete and additional procedures and therapies may be necessary [
         <a href="#rid40">
          40
         </a>
         ]. If the diagnosis is uncertain and the surgical risks (eg, facial nerve injury) preclude surgical excision, fine needle aspiration (FNA) may help establish the microbiologic diagnosis with minimal procedural risk. (See
         <a class="local">
          'Laboratory confirmation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2272513063">
         <span class="h2">
          Surgical excision (preferred)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – For patients with NTM or suspected NTM lymphadenitis and no evidence of pulmonary or disseminated disease, we suggest surgical excision without antimicrobial therapy as the initial intervention if complete excision can be performed safely (eg, without damage to the facial nerve (
         <a class="graphic graphic_figure graphicRef55677" href="/z/d/graphic/55677.html" rel="external">
          figure 1
         </a>
         )). The risk of injury to the facial nerve is increased in children with preauricular or intraparotid involvement. Surgical excision is curative and provides the optimal specimen for diagnostic testing [
         <a href="#rid1">
          1,2,40,71-75
         </a>
         ]. Incision and drainage generally are contraindicated because of the high probability of developing a chronically draining sinus tract and increased risk of recurrence [
         <a href="#rid1">
          1,59-62
         </a>
         ]. The management of pulmonary and disseminated NTM disease in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/85894.html" rel="external">
          "Nontuberculous mycobacterial pulmonary infections in children", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14425.html" rel="external">
          "Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial and observational studies, surgical excision has been associated with higher rates of cure, improved/more rapid healing, better cosmetic results, and fewer adverse effects than curettage, antimycobacterial therapy, or observation [
         <a href="#rid1">
          1,26,45,71,72,74,76
         </a>
         ]. In a meta-analysis of randomized and observational studies including &gt;1900 children with NTM lymphadenitis, the adjusted mean cure rate was greater for complete surgical excision (98 percent, 95% CI 97-99.5 percent) than for curettage (88 percent, 95% CI 70-97 percent), antimycobacterial therapy (73 percent, 95% CI 50-88 percent), or observation (70 percent, 95% CI 40-89 percent) [
         <a href="#rid40">
          40
         </a>
         ]. The rates of fistula formation were also lower with complete surgical excision than other interventions (2 versus 19 percent with curettage, 4 percent with antimycobacterial therapy, and 60 percent for observation). In one of the included trials, wound healing was shorter with excision than curettage (3.6 versus 11.4 weeks) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A randomized trial compared surgical excision with antimycobacterial therapy (
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">
          rifabutin
         </a>
         for at least 12 weeks and up to six months) in 100 children with NTM lymphadenitis (
         <em>
          M. avium
         </em>
         complex [MAC] was isolated in 71 percent; all of the isolates were macrolide susceptible) [
         <a href="#rid72">
          72
         </a>
         ]. The rate of cure (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months) was greater in the excision group (96 versus 66 percent). Surgical complications (wound infection, postoperative hematoma, facial nerve palsy) occurred in 28 percent of children in the excision group, while 78 percent of children in the antimycobacterial therapy group had adverse effects related to medication or disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Facial nerve palsy is an important complication of complete excision. Among 1077 children in the meta-analysis who underwent complete excision, transient facial nerve palsy occurred in 8 percent and permanent facial nerve palsy in 2 percent, compared with none of the children who were managed with curettage, antimycobacterial therapy, or observation [
         <a href="#rid40">
          40
         </a>
         ]. Less common complications of complete excision included fistula formation (2 percent), wound infection (2 percent), scar formation (2 percent), and additional intervention (8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative follow-up
         </strong>
         — Children with isolated NTM lymphadenitis that has been successfully excised can be discharged from follow-up when their wound is healed. However, they should be informed that there is a small (&lt;5 percent) risk of recurrence or development of new lesions [
         <a href="#rid72">
          72
         </a>
         ] and instructed to return to medical attention if they notice any changes in the lesion. Recurrences may be treated surgically or with antimycobacterial therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272513102">
         <span class="h2">
          Antimycobacterial therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – For children with isolated NTM lymphadenitis or suspected NTM lymphadenitis who are not candidates for surgical excision (eg, increased risk of facial nerve damage [eg, preauricular or intraparotid involvement (
         <a class="graphic graphic_figure graphicRef55677" href="/z/d/graphic/55677.html" rel="external">
          figure 1
         </a>
         )] or poor cosmetic result, established sinus tract, etc), we suggest antimicrobial therapy with or without subsequent gentle curettage rather than observation (ie, wait and see). The prolonged course of spontaneous resolution may make observation intolerable for some families [
         <a href="#rid13">
          13,77
         </a>
         ]. (See
         <a class="local">
          'Observation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Randomized and observational studies indicate that antimicrobial therapy, usually with a macrolide and another agent, has moderate success in clearing the lymphadenitis without surgical excision (resolution rates range from 50 to 100 percent) [
         <a href="#rid47">
          47,72,74,77-81
         </a>
         ]. However, patients who are treated with antibiotics alone may develop fistulous sinus tracts [
         <a href="#rid72">
          72
         </a>
         ]. In a meta-analysis of randomized and observational studies, among 171 children treated with antimycobacterial therapy, the adjusted mean cure rate was 73 percent (95% CI 50-88 percent); 4 percent developed fistulas and 31 percent required additional surgical intervention [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial that directly compared surgical excision with antimycobacterial therapy (
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">
          rifabutin
         </a>
         for at least 12 weeks and up to six months), 66 percent of patients treated with antibiotics were cured (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months), 32 percent developed draining fistula, and 78 percent had adverse effects related to medication or disease (eg, fever, fatigue, abdominal pain, tooth discoloration, headache, vomiting) [
         <a href="#rid72">
          72
         </a>
         ]. It is important to warn caregivers about the possibility of developing a draining fistula before starting antimycobacterial therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another randomized trial that directly compared observation and antimycobacterial therapy (
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">
          rifabutin
         </a>
         for 12 weeks) in 50 children with advanced NTM lymphadenitis (ie, fluctuance and skin discoloration), the median time to resolution was similar between groups (approximately 38 weeks) [
         <a href="#rid77">
          77
         </a>
         ]. In follow-up of at least two years, no recurrences were reported. In a subsequent observational study of children with NTM lymphadenitis who did not undergo surgery, median time to resolution was shorter with antibiotic therapy (rifabutin plus a macrolide) than observation (24 versus 44 weeks) [
         <a href="#rid82">
          82
         </a>
         ]. Ten children (eight in the observation group and two in the antibiotic therapy group) had recurrence at the same site during the 10-year follow-up period. Recurrence occurred in the first year after healing in three patients, in the second year in four patients, and later in three patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In observational and randomized trials, fistula formation is less common in children who are treated with antibiotic therapy than with observation (4 versus 60 to 70 percent) [
         <a href="#rid40">
          40,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regimen and duration
         </strong>
         – The empiric antimycobacterial regimen is determined by the likely causative species. The majority of NTM lymphadenitis is caused by MAC [
         <a href="#rid11">
          11,12
         </a>
         ]. In the United State
         <em>
          s, Mycobacterium simiae and M. fortuitum
         </em>
         are less common causes [
         <a href="#rid11">
          11
         </a>
         ]
         <em>
          . M. haemophilum
         </em>
         is more commonly detected in the Netherlands and other countries [
         <a href="#rid12">
          12-15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal duration of antimycobacterial therapy for lymphadenitis is unknown; patients typically are treated until their symptoms resolve (usually within three to six months) [
         <a href="#rid19">
          19,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MAC
         </strong>
         – Given the predominance of MAC in pediatric cervicofacial lymphadenitis, when antimicrobial treatment for NTM lymphadenitis is undertaken, and
         <em>
          M. tuberculosis
         </em>
         is not a concern, we suggest empiric therapy with a macrolide (
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ) in combination with
         <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">
          ethambutol
         </a>
         and/or
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         (or
         <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">
          rifabutin
         </a>
         ) (
         <a class="graphic graphic_table graphicRef132531" href="/z/d/graphic/132531.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid2">
          2,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This regimen is suggested based upon those in randomized trials, observational studies, and in vitro studies, with the caveat that, with the exception of macrolides and MAC, there is poor correlation between in vitro susceptibilities and clinical outcomes [
         <a href="#rid26">
          26,47,72,78,80,81
         </a>
         ]. Our suggested regimen is consistent with the recommendations of the American Thoracic Society, IDSA, and the AAP Committee on Infectious Diseases [
         <a href="#rid2">
          2,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          Clarithromycin
         </a>
         was used in early studies of MAC lymphadenitis; however,
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         may be preferable because it is more palatable and is dosed once per day [
         <a href="#rid84">
          84,85
         </a>
         ]. Although MAC is usually susceptible to macrolides, single-drug therapy with a macrolide increases the risk of development of mutational resistance [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           M. tuberculosis
          </em>
         </strong>
         <strong>
          not excluded
         </strong>
         – For children with suspected NTM lymphadenitis in whom
         <em>
          M. tuberculosis
         </em>
         remains a concern (eg, pending culture or polymerase chain reaction assay results in children with risk factors for
         <em>
          M. tuberculosis
         </em>
         ), the empiric antimicrobial regimen should include coverage for both NTM and
         <em>
          M. tuberculosis.
         </em>
         For preschool children who are more likely than older children to have NTM lymphadenitis and who may not tolerate the volume of medication required for combination therapy with five drugs, an appropriate regimen includes
         <a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">
          ethambutol
         </a>
         , and a macrolide (either
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ) (
         <a class="graphic graphic_table graphicRef132531" href="/z/d/graphic/132531.html" rel="external">
          table 2
         </a>
         ). For older children,
         <a class="drug drug_pediatric" data-topicid="12751" href="/z/d/drug information/12751.html" rel="external">
          pyrazinamide
         </a>
         is added [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The antibiotic regimen may need to be altered when definitive speciation is available. (See
         <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">
          "Tuberculosis disease in children: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Suspected or confirmed non-MAC species
         </strong>
         – The antibiotic regimen may need to be altered if a species other than MAC is suspected or confirmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           M. simiae
          </em>
         </strong>
         – The optimal therapeutic regimen for
         <em>
          M. simiae
         </em>
         has yet to be determined [
         <a href="#rid2">
          2
         </a>
         ]. Agents that appear to be active in vitro include
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">
          rifabutin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109477" href="/z/d/drug information/109477.html" rel="external">
          clofazimine
         </a>
         (not available in the United States),
         <a class="drug drug_pediatric" data-topicid="12807" href="/z/d/drug information/12807.html" rel="external">
          streptomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          moxifloxacin
         </a>
         (
         <a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           M. fortuitum
          </em>
         </strong>
         –
         <em>
          M. fortuitum
         </em>
         typically is susceptible to macrolides,
         <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">
          amikacin
         </a>
         , carbapenems, fluoroquinolones, and
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (
         <a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid2">
          2,88-93
         </a>
         ]. Single-agent therapy with a macrolide is not recommended because
         <em>
          M. fortuitum
         </em>
         has inducible macrolide resistance [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           M. haemophilum
          </em>
         </strong>
         – The optimal therapeutic regimen for
         <em>
          M. haemophilum
         </em>
         has yet to be determined [
         <a href="#rid2">
          2
         </a>
         ]. Agents that appear to be active in vitro include
         <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">
          amikacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         , and rifamycins (
         <a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid95">
          95-99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The antimycobacterial agents that are used to treat NTM lymphadenitis often are difficult to tolerate, and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with
         <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">
          amikacin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12807" href="/z/d/drug information/12807.html" rel="external">
          streptomycin
         </a>
         , optic neuropathy with
         <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">
          ethambutol
         </a>
         , and hepatotoxicity with
         <a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">
          isoniazid
         </a>
         (
         <a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">
          table 3
         </a>
         ). The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">
          "Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7214.html" rel="external">
          "Manifestations of and risk factors for aminoglycoside nephrotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/478.html" rel="external">
          "Ethambutol: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/474.html" rel="external">
          "Azithromycin and clarithromycin", section on 'Adverse reactions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/481.html" rel="external">
          "Isoniazid: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/477.html" rel="external">
          "Isoniazid hepatotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjunctive surgical therapy
         </strong>
         – FNA may help to decompress a large, fluctuant lymph node and may be warranted if the risk of developing a draining sinus tract is high (eg, central fluctuance with extension towards the skin, increased risk of paradoxical worsening after initiation of antimycobacterial therapy [eg, adolescent or young adult male]) [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Curettage may be indicated for children with bulky lymphadenopathy in whom surgical excision is not possible (eg, the node encompasses the facial nerve) but it is desirable to decrease the size of the lymph node (eg, to improve lateral rotation of the neck, to decrease the area of abscessed lymph nodes with poor penetration of antibiotics).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to therapy
         </strong>
         – The response to antimicrobial therapy for NTM lymphadenitis is monitored clinically. We suggest follow-up visits at approximately monthly intervals to ensure that patients are taking and tolerating their medications (if prescribed) and that their lymphadenitis is improving.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment failure
         </strong>
         – There is no standard definition for treatment failure. We consider patients who have no improvement of symptoms after six months of therapy or who have progression of symptoms during therapy to have treatment failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children who are not responding to what should be effective therapy, it is important to verify speciation and susceptibility testing and to make sure that the child has received antimycobacterial therapy as prescribed, recognizing that with the exception of macrolides and MAC, there is poor correlation between in vitro susceptibilities and clinical outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surgical excision, if it can be safely performed, may be warranted for patients who fail to improve or worsen during antimicrobial therapy for NTM lymphadenitis. (See
         <a class="local">
          'Surgical excision (preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are not surgical candidates, a change in the antimicrobial regimen and/or testing for
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         resistance may be warranted [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272513142">
         <span class="h2">
          Observation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We usually suggest against observation for children with NTM lymphadenitis, but it may be a feasible approach for caregivers wishing to avoid surgery. Given enough time, children with isolated NTM lymphadenitis will have resolution of disease without treatment [
         <a href="#rid13">
          13,70,77,82
         </a>
         ]. In an observational study of 92 children with NTM cervical lymphadenitis and minimal disease (eg, single node involvement, only 25 percent with skin changes), resolution of symptoms occurred within 6 months in 71 percent, within 9 months in 25 percent, and within 12 months in 2 percent [
         <a href="#rid13">
          13
         </a>
         ]. Purulent drainage lasted three to five weeks in 91 percent and eight weeks in 5 percent.
        </p>
        <p>
         Although resolution eventually occurs, many children with untreated NTM lymphadenitis develop sinus tracts with prolonged drainage [
         <a href="#rid10">
          10,40,77
         </a>
         ], and caregivers/patients may not be willing to tolerate a draining lesion on the face or neck for the six months (or longer) that may be required for spontaneous healing [
         <a href="#rid13">
          13,73
         </a>
         ]. In addition, recurrence is more common among children treated with observation [
         <a href="#rid83">
          83
         </a>
         ]. Nonetheless, in a cohort of 21 children with confirmed craniofacial NTM cervical lymphadenitis managed by observation alone whose caregiver completed a satisfaction questionnaire at a median of 6.8 years after presentation, all but one respondent expressed contentment with observation alone as a management strategy [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         In a meta-analysis of randomized and observational studies, among 157 children with NTM lymphadenitis who were managed with observation, the adjusted mean cure rate was 70 percent (95% CI 40-89 percent); 60 percent developed fistulas, 2 percent developed scars, and 3 percent required surgical intervention [
         <a href="#rid40">
          40
         </a>
         ]. In a long-term follow-up study (median 6.8 years, range 2.3 to 16.9 years) of 21 children with craniofacial NTM lymphadenitis, 18 patients had ≥1 scar; most of the scars were &lt;3 cm in length with normal pigmentation and a normal or only mildly uneven surface [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4007066347">
         <span class="h1">
          MANAGEMENT OF RECURRENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited evidence to guide treatment of recurrent nontuberculous mycobacterial (NTM) lymphadenitis following surgical excision or antimicrobial therapy. In clinical trials and observational studies, recurrent NTM lymphadenitis has been successfully treated with surgical excision (if it can be performed safely) or antimycobacterial therapy [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="local">
          'Surgical excision (preferred)'
         </a>
         above and
         <a class="local">
          'Antimycobacterial therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3052341426">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113062.html" rel="external">
          "Society guideline links: Nontuberculous mycobacteria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2272513150">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in otherwise healthy children. Most cases of NTM lymphadenitis in the United States are caused by
         <em>
          Mycobacterium avium
         </em>
         complex (MAC). Other commonly detected species include
         <em>
          Mycobacterium haemophilum, Mycobacterium simiae,
         </em>
         and
         <em>
          Mycobacterium fortuitum.
         </em>
         (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical findings
         </strong>
         – NTM lymphadenitis usually occurs in immunocompetent children between one and five years of age and involves the cervicofacial lymph nodes. It typically begins as a unilateral, nontender node that slowly enlarges over several weeks, during which fluctuance, violaceous discoloration, thinning of the overlying skin, and sinus drainage may develop (
         <a class="graphic graphic_picture graphicRef69475" href="/z/d/graphic/69475.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with NTM lymphadenitis generally have normal complete blood count, differential, erythrocyte sedimentation rate, and chest radiograph. (See
         <a class="local">
          'Laboratory features'
         </a>
         above and
         <a class="local">
          'Radiographic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – Definitive diagnosis requires detection of NTM with culture or polymerase chain reaction assay of fistula drainage, tissue, or caseous material. A presumptive diagnosis can be made if the clinical (eg, subacute/chronic unilateral lymphadenitis, violaceous discoloration) and/or histopathologic features (eg, positive acid-fast bacilli stains, granulomas) are compatible with NTM and other conditions in the differential diagnosis (including
         <em>
          Mycobacterium tuberculosis
         </em>
         ) have been excluded (
         <a class="graphic graphic_algorithm graphicRef131706" href="/z/d/graphic/131706.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of NTM lymphadenitis includes other infectious causes of unilateral lymphadenitis, benign cysts, and malignancy. A combination of clinical, radiographic, and laboratory findings (including serology and microbiologic testing) may be necessary to distinguish NTM lymphadenitis from these conditions. (See
         <a class="medical medical_review" href="/z/d/html/5982.html" rel="external">
          "Cervical lymphadenitis in children: Etiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6061.html" rel="external">
          "Cervical lymphadenitis in children: Diagnostic approach and initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with isolated NTM or suspected NTM lymphadenitis in a location with low risk of facial nerve injury (ie, excluding preauricular or intraparotid involvement), we suggest surgical excision without antimycobacterial therapy as the initial intervention (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Antimycobacterial therapy or observation alone are alternatives for children and families who wish to avoid surgery. Excision has higher cure rates, more rapid healing, and better cosmetic results than other interventions. (See
         <a class="local">
          'Surgical excision (preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with NTM who are not candidates for surgical excision, we suggest antimycobacterial therapy with or without gentle curettage rather than observation alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We prefer antimicrobial therapy to observation because the risk of fistula formation is lower. Observation is an alternative for patients and families who are concerned about adverse effects of a prolonged course of antimycobacterial therapy. (See
         <a class="local">
          'Antimycobacterial therapy'
         </a>
         above and
         <a class="local">
          'Observation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pending culture results in children for whom
         <em>
          M. tuberculosis
         </em>
         is not a concern, we usually treat with a macrolide (
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ) in combination with another agent (either a rifamycin or
         <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">
          ethambutol
         </a>
         ) (
         <a class="graphic graphic_table graphicRef132531" href="/z/d/graphic/132531.html" rel="external">
          table 2
         </a>
         ) given the predominance of MAC. Patients typically are treated until their symptoms resolve (usually three to six months). (See
         <a class="local">
          'Antimycobacterial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If
         <em>
          M. tuberculosis
         </em>
         remains a concern, we treat with at least four drugs (eg,
         <a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">
          ethambutol
         </a>
         , and macrolide). (See
         <a class="local">
          'Antimycobacterial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celdrán A, Esteban J, Mañas J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.
          </a>
         </li>
         <li class="breakAll">
          Parte AC. List of prokaryotic names with standing in nomenclature. Genus Mycobacterium. Available at: http://www.bacterio.net/mycobacterium.html (Accessed on October 04, 2019).
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Nontuberculous mycobacteria (environmental mycobacteria, mycobacteria other than Mycobacterium tuberculosis). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.814.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA, Kuijper EJ, Prins JM, et al. Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2006; 43:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J 2008; 27:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen YH, Amir J, Ashkenazi S, et al. Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis 2008; 14:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Marcos PW, Plaza-Fornieles M, Menasalvas-Ruiz A, et al. Risk factors of non-tuberculous mycobacterial lymphadenitis in children: a case-control study. Eur J Pediatr 2017; 176:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacroix A, Piau C, Lanotte P, et al. Emergence of Nontuberculous Mycobacterial Lymphadenitis in Children After the Discontinuation of Mandatory Bacillus Calmette and GuÉrin Immunization in France. Pediatr Infect Dis J 2018; 37:e257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliano D, Thomson R. The Epidemiology of Extrapulmonary Non-tuberculous Mycobacterial Infection in a Pediatric Population. Pediatr Infect Dis J 2020; 39:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham-Huy A, Robinson JL, Tapiéro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blyth CC, Best EJ, Jones CA, et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reuss AM, Wiese-Posselt M, Weissmann B, et al. Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 2009; 28:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haverkamp MH, Arend SM, Lindeboom JA, et al. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004; 39:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tebruegge M, Pantazidou A, MacGregor D, et al. Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis &amp; Management at a Tertiary Center. PLoS One 2016; 11:e0147513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuntz M, Kohlfürst DS, Feiterna-Sperling C, et al. Risk Factors for Complicated Lymphadenitis Caused by Nontuberculous Mycobacteria in Children. Emerg Infect Dis 2020; 26:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WJ, Kim TW, Shur KB, et al. Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000; 27:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Baum H, Bommer M, Forke A, et al. Is domestic tap water a risk for infections in neutropenic patients? Infection 2010; 38:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. J Infect Dis 2018; 218:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romanus V, Hallander HO, Wåhlén P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trnka L, Danková D, Svandová E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuber Lung Dis 1994; 75:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kontturi A, Soini H, Ollgren J, Salo E. Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016. Clin Infect Dis 2018; 67:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland AJ, Holland J, Martin HC, et al. Noncervicofacial atypical mycobacterial lymphadenitis in childhood. J Pediatr Surg 2001; 36:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA, Smets AM, Kuijper EJ, et al. The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Radiol 2006; 36:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmermann P, Tebruegge M, Curtis N, Ritz N. The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis. J Infect 2015; 71:9.
          </a>
         </li>
         <li class="breakAll">
          CDC Health Advisory. Outbreaks of nontuberculous mycobacterial infections highlight importance of maintaining and monitoring dental waterlines. Available at: https://emergency.cdc.gov/han/2022/han00478.asp (Accessed on November 01, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh J, O'Donnell K, Nieves DJ, et al. Invasive Mycobacterium abscessus Outbreak at a Pediatric Dental Clinic. Open Forum Infect Dis 2021; 8:ofab165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatzenbuehler LA, Tobin-D'Angelo M, Drenzek C, et al. Pediatric Dental Clinic-Associated Outbreak of Mycobacterium abscessus Infection. J Pediatric Infect Dis Soc 2017; 6:e116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penn R, Steehler MK, Sokohl A, Harley EH. Nontuberculous mycobacterial cervicofacial lymphadenitis--a review and proposed classification system. Int J Pediatr Otorhinolaryngol 2011; 75:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suskind DL, Handler SD, Tom LW, et al. Nontuberculous mycobacterial cervical adenitis. Clin Pediatr (Phila) 1997; 36:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staufner C, Sommerburg O, Holland-Cunz S. Algorithm for early diagnosis in nontuberculous mycobacterial lymphadenitis. Acta Paediatr 2012; 101:e382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazra R, Robson CD, Perez-Atayde AR, Husson RN. Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Clin Infect Dis 1999; 28:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson CD, Hazra R, Barnes PD, et al. Nontuberculous mycobacterial infection of the head and neck in immunocompetent children: CT and MR findings. AJNR Am J Neuroradiol 1999; 20:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvalho AC, Codecasa L, Pinsi G, et al. Differential diagnosis of cervical mycobacterial lymphadenitis in children. Pediatr Infect Dis J 2010; 29:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Planas A, Baquero-Artigao F, Santiago B, et al. Interferon-Gamma Release Assays Differentiate between Mycobacterium avium Complex and Tuberculous Lymphadenitis in Children. J Pediatr 2021; 236:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pong A, Moser KS, Park SM, et al. Evaluation of an Interferon Gamma Release Assay to Detect Tuberculosis Infection in Children in San Diego, California. J Pediatric Infect Dis Soc 2012; 1:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009; 28:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haimi-Cohen Y, Zeharia A, Mimouni M, et al. Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis. Clin Infect Dis 2001; 33:1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivas-Mazón R, Blázquez-Gamero D, Alberti-Masgrau N, et al. Diagnosis of nontuberculous mycobacterial lymphadenitis: the role of fine-needle aspiration. Eur J Pediatr 2021; 180:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel DE, Romaneschi KB. Surgical treatment of cervicofacial nontuberculous mycobacterial adenitis in children. Laryngoscope 1995; 105:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen RH, Illum P. Cervicofacial nontuberculous mycobacterial lymphadenitis in children. Dan Med J 2012; 59:A4349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spyridis P, Maltezou HC, Hantzakos A, et al. Mycobacterial cervical lymphadenitis in children: clinical and laboratory factors of importance for differential diagnosis. Scand J Infect Dis 2001; 33:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott CA, Atkinson SH, Sodha A, et al. Management of lymphadenitis due to non-tuberculous mycobacterial infection in children. Pediatr Surg Int 2012; 28:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taha AM, Davidson PT, Bailey WC. Surgical treatment of atypical mycobacterial lymphadenitis in children. Pediatr Infect Dis 1985; 4:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, et al. Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. J Clin Microbiol 2004; 42:2644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011; 24:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson ET, Samson D, Banaei N. Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR. J Clin Microbiol 2009; 47:1497.
          </a>
         </li>
         <li class="breakAll">
          www.gen-probe.com/products-services/culture-identification (Accessed on July 10, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus M, Benharroch D, Kaplan D, et al. Mycobacterial cervical lymphadenitis: the histological features of non-tuberculous mycobacterial infection. Histopathology 1999; 35:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morreale A, Dotta L, Vairo D, et al. When a Nontuberculous Mycobacterial Infection Reveals an Error of Immunity: A Single Center's Experience. Pediatr Infect Dis J 2022; 41:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandell DL, Wald ER, Michaels MG, Dohar JE. Management of nontuberculous mycobacterial cervical lymphadenitis. Arch Otolaryngol Head Neck Surg 2003; 129:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panesar J, Higgins K, Daya H, et al. Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review. Laryngoscope 2003; 113:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starke JR. Commentary: The natural history of nontuberculous mycobacterial cervical adenitis. Pediatr Infect Dis J 2008; 27:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA. Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children. J Oral Maxillofac Surg 2012; 70:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinelli G, Mannelli G, Arcuri F, et al. Surgical treatment for chronic cervical lymphadenitis in children. Experience from a tertiary care paediatric centre on non-tuberculous mycobacterial infections. Int J Pediatr Otorhinolaryngol 2018; 108:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA, Lindeboom R, Bruijnesteijn van Coppenraet ES, et al. Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Infect Dis J 2009; 28:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2011; 52:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger C, Pfyffer GE, Nadal D. Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. J Pediatr 1996; 128:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulter JB, Lloyd DA, Jones M, et al. Nontuberculous mycobacterial adenitis: effectiveness of chemotherapy following incomplete excision. Acta Paediatr 2006; 95:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luong A, McClay JE, Jafri HS, Brown O. Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis. Laryngoscope 2005; 115:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmerman MK, Morley AD, Buwalda J. Treatment of non-tuberculous mycobacterial cervicofacial lymphadenitis in children: critical appraisal of the literature. Clin Otolaryngol 2008; 33:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeboom JA. Long-term outcome of nonsurgical treatment of nontuberculous mycobacterial cervicofacial lymphadenitis in children. Oral Surg Oral Med Oral Pathol Oral Radiol 2021; 131:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyly A, Kontturi A, Salo E, et al. Childhood nontuberculous mycobacterial lymphadenitis-observation alone is a good alternative to surgery. Int J Pediatr Otorhinolaryngol 2020; 129:109778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele RW, Thomas MP, Bégué RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001; 20:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui D, Lim R, Tschen T, Rieder MJ. Assessment of the palatability of beta-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012; 39:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis 1994; 13:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson BA, Bocanegra R, Graybill JR. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother 1995; 39:2316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBride ME, Rudolph AH, Tschen JA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol 1991; 127:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristjansson M, Bieluch VM, Byeff PD. Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature. Rev Infect Dis 1991; 13:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plemmons RM, McAllister CK, Garces MC, Ward RL. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin Infect Dis 1997; 24:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz AT, Hernandez JA. Tuberculosis Cervical Adenitis: Management Dilemmas. Pediatr Infect Dis J 2016; 35:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haimi-Cohen Y, Markus-Eidlitz T, Amir J, Zeharia A. Long-term Follow-up of Observation-Only Management of Nontuberculous Mycobacterial Lymphadenitis. Clin Pediatr (Phila) 2016; 55:1160.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86045 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18312877" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32797222" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4045242" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17655974" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504281" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mycobacterium goodii infections associated with surgical implants at Colorado hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15243051" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795100" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20661106" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mycobacterial infections in Texas children: a 5-year case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17109286" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18787500" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18760014" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325250" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28265761" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk factors of non-tuberculous mycobacterial lymphadenitis in children: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29570591" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Emergence of Nontuberculous Mycobacterial Lymphadenitis in Children After the Discontinuation of Mandatory Bacillus Calmette and GuÉrin Immunization in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32235244" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Epidemiology of Extrapulmonary Non-tuberculous Mycobacterial Infection in a Pediatric Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12205297" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nontuberculous mycobacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7618936" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21532791" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16089239" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nontuberculous mycobacteria in children: a changing pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636280" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nontuberculous mycobacterial infection in children: a prospective national study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19561429" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356803" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26812154" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis&amp;Management at a Tertiary Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32091372" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk Factors for Complicated Lymphadenitis Caused by Nontuberculous Mycobacteria in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11747738" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nontuberculous mycobacterial disease following hot tub exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21921222" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pedicure-associated rapidly growing mycobacterial infection: an endemic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10824491" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20237946" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Is domestic tap water a risk for infections in neutropenic patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16732163" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15639625" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Biofilm formation and dispersal and the transmission of human pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29635431" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579311" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7841428" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29584893" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11528601" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Noncervicofacial atypical mycobacterial lymphadenitis in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16906393" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25727993" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25727993" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34113683" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Invasive Mycobacterium abscessus Outbreak at a Pediatric Dental Clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28903524" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pediatric Dental Clinic-Associated Outbreak of Mycobacterium abscessus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22014500" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nontuberculous mycobacterial cervicofacial lymphadenitis--a review and proposed classification system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241478" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nontuberculous mycobacterial cervical adenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22536978" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Algorithm for early diagnosis in nontuberculous mycobacterial lymphadenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10028082" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10588104" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Nontuberculous mycobacterial infection of the head and neck in immunocompetent children: CT and MR findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20160660" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Differential diagnosis of cervical mycobacterial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33984332" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Interferon-Gamma Release Assays Differentiate between Mycobacterium avium Complex and Tuberculous Lymphadenitis in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28052967" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20577159" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26618694" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Evaluation of an Interferon Gamma Release Assay to Detect Tuberculosis Infection in Children in San Diego, California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633512" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11595991" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17599309" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33205252" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diagnosis of nontuberculous mycobacterial lymphadenitis: the role of fine-needle aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564828" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Surgical treatment of cervicofacial nontuberculous mycobacterial adenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22239836" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cervicofacial nontuberculous mycobacterial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11440222" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mycobacterial cervical lymphadenitis in children: clinical and laboratory factors of importance for differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22438045" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Management of lymphadenitis due to non-tuberculous mycobacterial infection in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4080582" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Surgical treatment of atypical mycobacterial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15184446" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21976605" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297596" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297596" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583577" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycobacterial cervical lymphadenitis: the histological features of non-tuberculous mycobacterial infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35086117" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : When a Nontuberculous Mycobacterial Infection Reveals an Error of Immunity: A Single Center's Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12622546" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Management of nontuberculous mycobacterial cervical lymphadenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12514400" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17366449" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18787499" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Commentary: The natural history of nontuberculous mycobacterial cervical adenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21741739" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29605343" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Surgical treatment for chronic cervical lymphadenitis in children. Experience from a tertiary care paediatric centre on non-tuberculous mycobacterial infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19773678" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21288841" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774511" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449024" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Nontuberculous mycobacterial adenitis: effectiveness of chemotherapy following incomplete excision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222188" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19126128" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of non-tuberculous mycobacterial cervicofacial lymphadenitis in children: critical appraisal of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33358987" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Long-term outcome of nonsurgical treatment of nontuberculous mycobacterial cervicofacial lymphadenitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31756659" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Childhood nontuberculous mycobacterial lymphadenitis-observation alone is a good alternative to surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176558" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Compliance issues related to the selection of antibiotic suspensions for children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9193246" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Assessment of the palatability of beta-lactamase-resistant antibiotics in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22099521" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4083863" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1317144" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2069387" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1386098" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181357" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Activities of linezolid against rapidly growing mycobacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2327761" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19171799" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7698118" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Mycobacterium haemophilum: an emerging pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8619588" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991007" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1962107" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9142810" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27273690" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Tuberculosis Cervical Adenitis: Management Dilemmas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26603584" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Long-term Follow-up of Observation-Only Management of Nontuberculous Mycobacterial Lymphadenitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
